Journal Highlight : Translational Cancer Research
The journal welcomes scholarly contributions related to the translation of basic, molecular, and experimental cancer research into clinical applications and patient-centered oncology care. This section focuses on research that bridges fundamental cancer discoveries with clinical practice to improve cancer diagnosis, therapeutic strategies, disease monitoring, and overall patient outcomes.
The journal encourages submissions in areas including Translational Oncology, Clinical and Experimental Cancer Research, Cancer Biomarker Discovery, Molecular and Cellular Oncology, Precision Oncology, Targeted Cancer Therapies, Immuno-Oncology, Cancer Pharmacology, and Clinical Applications of Molecular Medicine. Research related to Tumor Biology, Cancer Genomics, Liquid Biopsy Technologies, Cancer Immunotherapy, Drug Resistance Mechanisms, Companion Diagnostics, and Translational Therapeutic Development is also welcomed.
Submissions focusing on Preclinical Cancer Models, Clinical Translation of Experimental Therapies, Biomarker-Guided Treatment Strategies, Personalized Cancer Medicine, Cancer Imaging and Molecular Diagnostics, AI and Bioinformatics in Oncology, Clinical Trial Translation, and Predictive and Prognostic Oncology Research are encouraged. The journal also welcomes studies investigating mechanisms of cancer progression, metastasis, therapeutic response, and translational approaches that improve evidence-based oncology practice.
Accepted manuscript types include Original Research Articles, Systematic Reviews, Meta-Analyses, Experimental and Preclinical Studies, Clinical Translational Studies, Case Reports, Clinical Trial Reports, and Technology and Methodology Articles that contribute to advancements in translational cancer research and clinical oncology.
Through this focus area, the journal aims to support research that accelerates the translation of scientific discoveries into clinical cancer care, advances personalized and targeted oncology strategies, improves diagnostic and therapeutic precision, and contributes to innovative and evidence-based cancer management worldwide.
